Portfolio
To address AMR and protect the lives of people around the world, PACE is providing funding and support for a portfolio of early-stage projects to help grow the pipeline of high-quality antimicrobial therapeutics and associated diagnostics.
Supporting the best innovations to address the global threat of AMR
We are supporting a diverse portfolio of projects aimed at developing new tests and treatments for bacterial infections with high unmet need. Through a series of funding rounds available to academics and SMEs worldwide, we are selecting, investing in and supporting the most promising projects. We are offering a collaborative approach to project development through access to advisors, mentors, potential project partners and enabling technologies and capabilities. By supporting the projects in this way, we are helping to give them the best chance of success and position them for onward funding, investment and development. More projects will enter the portfolio as the programme progresses. This page highlights the innovators and projects that are currently in the PACE portfolio.
Number of projects supported
PACE funds committed to projects
Number of organisations funded
Project title: Advancing a direct-acting, small molecule antibacterial with Gram negative specificity and a novel mechanism of action
Project title: Optimisation of rhamnose presentation for next generation Alphamers® for the treatment of Gram-negative infections
Project title: Monoclonal antibodies targeting bacterial GAPDH as a single immunotherapy to treat infections caused by E. coli and Klebsiella pneumoniae
Project title: Leucyl-tRNA synthetase inhibitor for oral therapy of urinary tract infections
Project title: Engineered Phage Therapeutics (EPTs) to treat P. aeruginosa infections in bronchiectasis patients
Project title: Lead optimisation of mAbs targeting Acinetobacter baumannii iron acquisition proteins